Clinical Trial Update: Nicotinic Receptor Augmentation of SSRI Antidepressants [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating augmentation of SSRI antidepressants with nicotinic receptor modulation in depressive disorder; the study has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Depressive Disorder

Snippet

Sponsor: Yale University | Conditions: Depressive Disorder | Phase 2 | Status: COMPLETED